Results 81 to 90 of about 2,997 (217)

Towards personalized treatment of prostate cancer: PSMA I&T, a promising prostate-specific membrane antigen-targeted theranostic agent [PDF]

, 2016
Prostate-specific membrane antigen (PSMA) is a well-established target for nuclear imaging and therapy of prostate cancer (PCa). Radiolabeled small-molecule PSMA inhibitors are excellent candidates for PCa theranostics-they rapidly and efficiently ...
Boerman, O.C. (Otto), Chatalic, K.L.S. (Kristell), Clahsen-van Groningen, M.C. (Marian), Franssen, G.M. (Gerben), Heskamp, S. (Sandra), Jong, M. (Marcel) de, Konijnenberg, M. (Mark), Molkenboer-Kuenen, J.D.M. (Janneke D.M.), Schottelius, M. (Margret), Weerden, W.M. (Wytske) van, Wester, H.-J. (Hans-Jürgen)   +10 more
core   +1 more source

Current and Future Use of Long Axial Field-of-View Positron Emission Tomography/Computed Tomography Scanners in Clinical Oncology [PDF]

, 2023
The latest technical development in the field of positron emission tomography/computed tomography (PET/CT) imaging has been the extension of the PET axial field-of-view.
Brouwers, Adrienne H, Dierckx, Rudi A J O, Glaudemans, Andor W J M, Lammertsma, Adriaan A, Li, Zekai, Mohr, Philipp, Mostafapour, Samaneh, Noordzij, Walter, Providência, Laura, Roya, Mostafa, Slart, Riemer H J A, Tsoumpas, Charalampos, van Sluis, Joyce, van Snick, Johannes H, Willemsen, Antoon T M   +14 more
core   +2 more sources

Antibody–Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions

MedComm, Volume 7, Issue 4, April 2026.
Antibody–drug conjugates integrate antibody targeting with potent cytotoxic payloads to enable precision cancer therapy. Their clinical performance depends on coordinated optimization of engineering design, tumor antigen biology, and treatment strategy. Lessons from uro‐oncological malignancies illustrate how ADCs can be effectively developed, combined,
Bisheng Cheng, Lanqi Gong, Zongwei Wang, Peidan Peng, Kewei Xu, Hai Huang, Peng Wu   +6 more
wiley   +1 more source

ImmunoPET provides a novel way to visualize the CD103+ tissue-resident memory T cell to predict the response of immune checkpoint inhibitors

EJNMMI Research
Background Immune checkpoint inhibitors (ICIs) have made significant progress in oncotherapy improving survival of patients. However, the benefits are limited to only a small subgroup of patients who could achieve durable responses.
Xiaoyu Fan, Hans W. Nijman, Marco de Bruyn, Philip H. Elsinga   +3 more
doaj   +1 more source

Improvement of Radioimmunotherapy Using Pretargeting [PDF]

, 2013
During the past two decades, considerable research has been devoted to radionuclide therapy using radiolabeled monoclonal antibodies and receptor binding agents.
Caroline Bodet-Milin, Caroline Rousseau, Eric Frampas, Françoise Kraeber-Bodéré, Jacques Barbet, Jean-Francois Chatal   +5 more
core   +1 more source

Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Companion diagnostics use biomarker‐based assays to stratify patients for precision therapies, improving outcomes while reducing ineffective treatment and side effects. This review summarizes the evolution, regulatory landscape, clinical applications, and technological platforms of CDx, highlighting their role in biomarker‐driven precision therapy.
Yuesong Wu, Rou Xue, Xiangwen Luo, Jiangnan Liao, Zongbo Zhang, Jinhai Deng, Teng Liu, Xin Li, Zhe‐Sheng Chen, Mingzhu Yin   +9 more
wiley   +1 more source

Noninvasive imaging of amyloid‐beta and tau in rodent and nonhuman primate models

VIEW, Volume 7, Issue 1, February 2026.
Imaging of amyloid‐beta plaque and tau accumulation in rodent and nonhuman primate model of Alzheimer's disease. Created in BioRender. Ni R. 2026. https://BioRender.com/a97h5ec Abstract Neurodegenerative diseases are characterized by the aberrant accumulation of protein aggregates.
Ruiqing Ni, Axel Rominger
wiley   +1 more source

Novel Preparation Methods of ⁵²Mn for ImmunoPET Imaging [PDF]

Bioconjugate Chemistry, 2015
(52)Mn (t1/2 = 5.59 d, β(+) = 29.6%, Eβave = 0.24 MeV) shows promise in positron emission tomography (PET) and in dual-modality manganese-enhanced magnetic resonance imaging (MEMRI) applications including neural tractography, stem cell tracking, and biological toxicity studies.
Graves, Stephen A., Hernandez, Reinier, Fonslet, Jesper, England, Christopher G., Valdovinos, Hector F., Ellison, Paul A., Barnhart, Todd E., Elema, Dennis Ringkjøbing, Theuer, Charles P., Cai, Weibo, Nickles, Robert J., Severin, Gregory   +11 more
openaire   +3 more sources

Site-specific 68Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models

EJNMMI Radiopharmacy and Chemistry, 2023
Background CD70-CD27 is a costimulatory ligand-receptor pair in the tumor necrosis factor receptor family. With only limited expression in normal tissues, CD70 is constitutively expressed in a variety of solid tumors and hematologic malignancies ...
Jonatan Dewulf, Tal Flieswasser, Tim Delahaye, Christel Vangestel, Alan Miranda, Hans de Haard, Julie Jacobs, Evelien Smits, Tim Van den Wyngaert, Filipe Elvas   +9 more
doaj   +1 more source

Antibody engineering & therapeutics, the annual meeting of the antibody society December 7-10, 2015, San Diego, CA, USA [PDF]

, 2016
The 26th Antibody Engineering & Therapeutics meeting, the annual meeting of The Antibody Society united over 800 participants from all over the world in San Diego from 6-10 December 2015.
Bakker, J, Bradbury, AR, Carter, PJ, Lund-Johansen, F, Melis, JP, Pauthner, M, Reichert, JM, Ullman, C, Wurch, T, Yeung, J   +9 more
core   +1 more source